| 1 | 自身免疫性肝炎相关原发性肝癌的临床特征、治疗及预后显示文摘目的总结自身免疫性肝炎(autoimmune hepatitis,AIH)相关原发性肝癌(primary liver cancer,PLC)的临床特征、治疗及患者生存情况。方法回顾性分析2012年1月至2016年12月我院诊断的在AIH基础上发生PLC的患者总计13例,总结患者的性别、发病年龄、肝硬化情况、AFP水平、肿瘤分期、患者的治疗选择及生存时间。结果13例患者中男5例,女8例。首次诊断PLC的平均年龄为61.8岁,肝癌发病率为2.3%。92.3%(12/13)的患者有肝硬化,其中Child-Pugh B级肝功能者10例。多数患者AFP不高,AFP>200 ng/ml者1例,患者的最大肿瘤直径为(3.1±1.9)cm(1.5~8.5 cm)。保守治疗3例,其余患者采用TACE、消融、肝部分切除、肝移植等单独及联合治疗,13例患者的中位生存时间为15个月。肝移植患者的生存时间明显优于其他治疗。结论AIH相关PLC往往发生在肝硬化失代偿期,患者肝功能多数较差,多数患者AFP不高,肿瘤分期较早,相对其他治疗,肝移植可能更能延长患者的生存时间。 | 生守鹏 王海燕 李建军 张洪海 孙玉 马良 张永宏 | 2020 | 胃肠病学和肝病学杂志2020，29，1： | 13 |
| 2 | 自身免疫性肝炎相关肝癌的临床特点和预后分析显示文摘目的探讨自身免疫性肝炎(AIH)相关肝癌(HCC)的临床特点和预后危险因素。方法回顾解放军三零二医院2008年5月113至2013年4月3013收治的40例AIH相关肝癌患者临床资料,分析AIH-HCC患者的临床特点和预后危险因素。结果40例AIH—HCC患者确诊肝癌时的年龄28—76岁不等,平均(55.1±13.5)岁。AIH肝硬化患者发展为肝癌的时间间隔为(49.2±44.5)个月(范围3~194个月)。AIH—HCC患者的中位生存期为(16.0±4.0)个月(范围1~44个月),1年生存率为54.0%。单因素分析显示AFP水平较高、肿瘤直径较大、肿瘤个数较多与患者预后较差有关(P〈0.05);而性别、年龄、IAIHG评分、AIH分型、输血史、饮酒史、吸烟史对患者生存期无明显影响(P〉0.05)。多因素回归分析结果表明,AFP水平及肿瘤个数为影响预后的独立危险因素。对比多种治疗方案,绝大多数患者接受了肝动脉化疗栓塞治疗,但接受外科手术的患者生存率明显高于TACE或保守治疗。结论肝硬化是AIH患者发展为肝癌必然经历的过程。肝硬化后的每年肝癌发生率为1.65%。AFP阴性、肿瘤单发的AIH—HCC患者预后较好。与其他方法比较,外科手术治疗可以延长患者生存时间。 | 王继涛 朱震宇 王冰 张绍庚 孙百军 | 2014 | 中华肝胆外科杂志2014，20，3： | 9 |
| 3 | Auto immune hepatitis显示文摘To provide an update of the latest trends in epidemiology, clinical course, diagnostics, complications and treatment of auto immune hepatitis(AIH). A search ofthe MEDLINE database was performed using the search terms: 'auto immune hepatitis', 'clinical presentation', 'symptoms', 'signs', 'diagnosis', 'auto antibodies', 'laboratory values', 'serology', 'histopathology', ' h i s t o l o g y ', ' g e n e t i c s ', 'HLA g e n e s ', 'non-HLA genes', 'environment', 'epidemiology', 'prevalence', 'incidence', 'demographics', 'complications', 'HCC', 'PBC', 'PSC', 'corticosteroid', 'therapy', 'treatment', 'alternative treatment'. English-language full-text articles and abstracts were considered. Articles included reviews, meta-analysis, prospective retrospective studies. No publication date restrictions were applied. AIH is an immune meditated progressive inflammatory liver disease that predominantly affects middle-aged females but may affect people of all ages. The clinical spectrum of AIH is wide, ranging from absent or mild symptoms to fulminant hepatic failure. The aetiology of AIH is still unknown, but is believed to occur as the consequence of an aberrant immune response towards an un-known trigger in a genetically susceptible host. In the absence of a gold standard, diagnosis is based on the combination of clinical, biochemical and histopathological criteria. Immunosuppressive treatment has been the cornerstone of treatment since the earliest description of the disease in 1950 by Waldenstr?m. Such treatment is often successful at inducing remission and generally leads to normal life expectancy. Nevertheless, there remain significant areas of unmet aetiological a clinical needs including fundamental insight in disease pathogenesis, optimal therapy, duration of treatment and treatment alternatives in those patients unresponsive to standard treatment regimens. | nicole mf van gerven ynto s de boer chris jj mulder carin mj van nieuwkerk gerd bouma | 2016 | World Journal of Gastroenterology2016，22，19： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员